Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.53, $0.28 better than the analyst estimate of $0.25. Revenue for the quarter came in at $99.5 million versus the consensus estimate of $92.73 million.

GUIDANCE:

Catalyst Pharmaceuticals sees Q3 2023 revenue of $380-390 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.